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Abstract
Background: Plasma levels of high-density lipoprotein cholesterol (HDL-C) have been associated to cardiovascular
disease. The high heritability of HDL-C plasma levels has been an incentive for several genome wide association
studies (GWASs) which identified, among others, variants in the first intron of the GALNT2 gene strongly associated
to HDL-C levels. However, the lead GWAS SNP associated to HDL-C levels in this genomic region, rs4846914, is
located outside of transcription factor (TF) binding sites defined by chromatin immunoprecipitation followed by
DNA sequencing (ChIP-seq) experiments in the ENCODE project and is therefore unlikely to be functional. In this
study we apply a bioinformatics approach which rely on the premise that ChIP-seq reads can identify allele specific
binding of a TF at cell specific regulatory elements harboring allele specific SNPs (AS-SNPs). EMSA and luciferase
assays were used to validate the allele specific binding and to test the enhancer activity of the regulatory element
harboring the AS-SNP rs4846913 as well as the neighboring rs2144300 which are in high LD with rs4846914.
Findings: Using luciferase assays we found that rs4846913 and the neighboring rs2144300 displayed allele specific
enhancer activity. We propose that an inhibitor binds preferentially to the rs4846913-C allele with an inhibitory
boost from the synergistic binding of other TFs at the neighboring SNP rs2144300. These events influence the
transcription level of GALNT2.
Conclusions: The results suggest that rs4846913 and rs2144300 drive the association to HDL-C plasma levels
through an inhibitory regulation of GALNT2 rather than the reported lead GWAS SNP rs4846914.
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Introduction
Low plasma levels of high-density lipoprotein cholesterol
(HDL-C) are strongly associated with high risk of coron-
ary artery disease (CAD). Low HDL-C levels together
with high levels of low-density lipoprotein cholesterol
(LDL-C) and triglycerides (TG) are common features of
dyslipidemia and combined hyperlipidemia [1]. Plasma
levels of HDL-C have a heritability of 40–60 % [2] and
several genome wide association studies (GWAS) [3, 4]
have been performed to pinpoint the associated genetic
variants. Variations in the first intron of the GALNT2
gene on chromosome 1q42 have been associated with
HDL-C and TG plasma levels in several studies [3, 5].
GALNT2 encodes for N-actetylgalactosaminyltransferase
2, an enzyme involved in the O-linked glycosylation of
proteins [6]. It glycosylates apolipoprotein C-III which is
an inhibitor of lipoprotein lipase (LPL). LPL hydrolyses
plasma triglycerides in very low-density lipoprotein
(VLDL) and chylomicrons [7] that influence HDL-C and
triglyceride levels. Overexpression of Galnt2 in mouse
models lowered HDL-C while knock-down of Galnt2 re-
sulted in higher HDL-C levels [4] and GALNT2 expres-
sion in liver is correlated to the lead GWAS SNP
(rs4846914) associated to HDL-C plasma levels [8].
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The SNP reported with the strongest association in
GWAS rarely is the functional one. Previous studies
have shown that SNPs associated to disease are enriched
in regulatory elements [9] and it is generally assumed
that the ones driving the association affect the activity of
a gene and that this is mediated by a transcription factor
(TF) binding with different strength to the two alleles,
variants, of the SNPs. We have therefore scanned public
data to find such SNPs and we utilized the TF binding
data from ENCODE ChIP-seq experiments [10] in the
epithelial hepatocellular carcinoma cell line HepG2 to
identify cis-acting regulatory variants that are relevant
for liver function (see Methods). SNPs in transcription
factor binding sites (TFBS) that showed an allele specific
binding (AS-SNPs) are suggested to be the drivers of the
associations observed in GWAS studies. The lead SNP
associated to HDL-C plasma levels was not located in a
regulatory element and therefore not likely to mediate
the association so in this study we tested the functional
activity of an AS-SNP in high linkage disequilibrium
(LD) with the lead GWAS SNP.
Methods
AS-SNPs definition
AS-SNPs were defined by our in house AS-SNPs selec-
tion pipeline which identifies heterozygous SNPs that
show a statistically significant difference in ChIP-seq
read count on the two alleles. The pipeline follows these
steps: (1) publicly available raw reads (.fastq) from ChIP-
seq for several TFs in HepG2 were obtained from the
ENCODE project database (ftp://hgdownload.cse.ucs-
c.edu/goldenPath/hg19/encodeDCC/) and were aligned
to the reference human genome (G1) UCSC hg19 as-
sembly based on the Genome Reference Consortium
Human genome build 37 (GRCh37) but excluding
random and unplaced contigs and to an HepG2-specific
alternative genome (G2), built using the FastaAlterna-
teReferenceMaker GATK utility that generates an alter-
native reference sequence replacing the reference bases
at variation sites with the bases supplied by a SNPs col-
lection. SNP calls were made from pooled short-read
datasets in house ChIP-seq data plus ENCODE genomic
HepG2 reads and were validated using a genome-wide
genotyping array. (2) Reads mapped specifically to G1 or
G2 were counted at the heterozygous SNPs. SNPs with
no reads mapped on G1 or G2 were discarded. (3) To
determine whether the G1/G2 read counts difference
was statistically significant a binomial test was applied
against the null hypothesis of an equal G1:G2 coverage.
After correcting for multiple testing (Benjamini & Hoch-
berg or FDR), AS-SNPs with P < 0.05 were selected. (4)
AS-SNPs were then intersected with the 1,000 Genomes
SNPs collection (1000 Genomes project, phase1_relea-
se_v3.20101123) in order to retrieve AFs. (5) Extensive
filtering of the selected AS-SNPs was performed to re-
move AS-SNPs that were in centromeric or telomeric
regions (UCSC Gap table ± 1 Mb), blacklisted ENCODE
regions (±100 bp) or CNVs. (6) Pruned AS-SNPs selec-
tions were finally intersected with collections of GWAS
associated to liver-related and metabolic relevant traits
and SNPs in LD (r2 > 0.8) with GWAS (proxy SNPs cal-
culated via SNAP tool [11]) to select candidate func-
tional AS-SNPs for experimental validation.
Cell cultures
HepG2 cells were cultured in RPMI 1640 medium sup-
plemented with 10 % non-inactivated FBS, L-glutamine
and a solution stabilized, with 10,000 units penicillin
and 10 mg streptomycin/mL, sterile-filtered, BioReagent,
suitable for cell culture (Sigma-Aldrich) at 37 °C with
5 % CO2.
Construction of cloning plasmids and luciferase reporter
assays
All the luciferase expression constructs were built based
on pGL4.23 from Promega. The ccdB expression cas-
sette was inserted into KpnI and EcoRV sites of pGL4.23
to construct pGL4.23-ccdB, which was used as a basal
vector to diminish false positive signal during the clon-
ing process. Genomic sequences surrounding AS-SNPs
were amplified by Phusion Hot Start Flex DNA polymer-
ase (NEB) using HepG2 genomic DNA as template. The
amplified fragments were purified by the QIAquick Gel
Extraction Kit (QIAGEN) and inserted upstream of the
minimal promoter sequence of pGL4.23 by SLiCE
cloning methods [12]. To test both of the alleles of the
AS-SNP, multiple individual clones were picked and sub-
jected to Sanger sequencing. HepG2 cells were trans-
fected one day after plating with approximately 90 %
confluence in 96-well plate. All the transfection reac-
tions were carried out with the X-tremeGENE HP DNA
transfection reagent (Roche). To normalize the transfec-
tion and lysis efficiency each well was transfected with
100 ng of firefly luciferase reporter vector harboring re-
spective AS-SNP alleles together with 1 ng of renilla lu-
ciferase reporter vector pGL4.74,. Twenty-four hours
after transfection, the cells were harvested and lysed in
1X passive lysis buffer (Promega) on a rocking platform
for 45 min at room temperature. Firefly and luciferase
activity were measured by Dual-Luciferase® Reporter
(DLR™) Assay System (Promega) on an Infinite® M200
pro reader (TECAN) following instructions provided
by the manufacturer. The ratios of firefly luciferase ac-
tivity to renilla luciferase activity were calculated and
expressed as Relative Luciferase Units (RLU) in the
figures. All data came from six replicate wells, and p-
values comparing RLU difference between AS-SNPs
alleles were calculated using two-tailed t-test.
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EMSA
Nuclear extracts were prepared from HepG2 cells using
the NucBuster™ Protein Extraction kit (Novagen) and
the amount was verified via the Qubit® Protein Assay
Kit (Life Technologies). Oligonucleotide probes were
designed with both alleles of rs4846913 flanked by
14 bp in both a cold and 5'-biotinylated form (IDT). Bi-
otinylated and un-biotinylated oligonucleotides were
annealed with the reverse complementary oligonucleo-
tide (95 °C to 25 °C temperature stepdown). For the
binding reaction, 3–6 μg of the nuclear extract were in-
cubated with 200 fmol of each biotinylated dsDNA
probe for 40 min on ice in 10 mM TrisHCl, 30 mM
KCl, 1 mM DTT, 1 μg of Poly (dI-dC), 7.5 % glycerol,
0.063 % NP-40, 2 mM MgCl2, and 0.1 mM EDTA.
Samples were electrophoresed in Criterion™ 5 % TBE
Precast Gels (Bio-rad), and electro-transferred into a
Genescreen plus™ hybridization transfer membrane
(Perkin Elmer). DNA-protein complexes were cross-
linked using UV-light and detected by chemilumines-
cence using LightShift® Chemiluminescent EMSA Kit
(Thermo Scientific).
Results and Discussion
We identified a collection of AS-SNPs showing differ-
ential allele binding of TFs based on ChIP-seq experi-
ments performed in HepG2 cells. The preferential TF
binding to a specific allele at heterozygous position
in the genome was used to pinpoint putative func-
tional regulatory elements. To avoid a bias toward
the reference human genome the ChIP-seq reads
were aligned to the maternal and paternal genomes
in HepG2. The difference in the number of reads
mapping to the two alleles was calculated and tested
for statistical significance in order to identify suitable
candidate regulatory elements for experimental valid-
ation (see Methods).
Here we selected an AS-SNP in high LD with differ-
ent GWAS SNPs associated to four traits related to
phospholipids/cholesterol levels (Table 1). These are
liver specific traits whose molecular events might be
explained by the liver derived cell line HepG2, namely
HDL-C and TG plasma levels associated to rs2144300,
HDL-C associated to rs10489615, metabolite levels as-
sociated to rs10127775 and HDL-C, TG associated to
rs4846914. Three out of four GWAS SNPs are located
outside of TFBS annotated by ChIP-seq experiments,
while rs2144300 is located on the edge of the regulatory
element harboring rs4846913 (Fig. 1a).
We investigated the regulatory effect of rs4846913, an
AS-SNP identified from ChIP-seq experiments in
HepG2 cells (see Methods). This variant is located in the
first intron of GALNT2 and is in high LD (r2 > 0.8) with
these four GWAS SNPs (Fig. 1a). The ENCODE project
has performed ChIP-seq of the TF CEBPB in HepG2
cells and alignment of the reads to rs4846913 showed a
genome-wide significant difference between the refer-
ence (C) and alternative (A) alleles.
We tested both alleles in EMSA and confirmed the
differential binding with a stronger protein binding for
the C allele (Fig. 1b). We then investigated the func-
tional activity of both alleles using a dual luciferase as-
says. We found that the tested fragments showed a
strong enhancer activity and a significantly lower signal
for the C than the A allele suggesting that the TF that
preferentially bind the C allele has a repressive activity.
The tested fragments contain rs4846913 and rs2144300
(Fig. 1c, top fragment). To investigate if both SNPs are
functional, we cloned rs4846913 separately in a smaller
fragment and tested in a luciferase assay. We found a
significant difference between the two alleles but the dif-
ference was significantly smaller compared to when both
SNPs were present (Fig. 1c, bottom fragment). The func-
tional activity of the rs4846913-A allele was the same for
the small and large fragment indicating that it is in-
dependent of the genomic context (Fig. 1c). This sug-
gests that a repressor binds to rs4846913-C allele and
another repressor to the rs2144300-C allele. Analysis
of motifs suggests that the TF ZBTB3 binds preferen-
tially to the rs4846913-C allele and that TFs PLAGL1
and NR3C2 may bind to the rs2144300-C allele and
act as repressors.
Table 1 GWAS and AS-SNPs in high LD at GALNT2
Chr_id Chr_pos (hg19) AS-SNP RegulomeDB† In LD‡ with GWAS SNP Associated traits
1 230294715 rs4846913 4 rs2144300a HDL-C, TG
1 230294715 rs4846913 4 rs4846914b HDL-C, TG
1 230294715 rs4846913 4 rs10489615c HDL-C
1 230294715 rs4846913 4 rs10127775d Metabolite levels
† Regulome DB score as an index of regulatory activity [14]
‡ LD with r2 ≥ 0,8
a[3, 15]
b[4, 5, 16, 17]
c[18]
d[19]
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The genomic distribution of the GWAS SNPs
(Table 1) supports the recent observation that several
GWAS-SNPs can be associated to the same AS-SNP
(e.g. rs4846913). Thereby a single functional AS-SNP
can be causative and therefore the genetic driver of
the association. This can be the case for several
GWAS SNPs associated to one or more traits
(Table 1) as observed previously for AS-SNPs in dif-
ferent cell lines [13]. This indicates that the statistical
association to a trait in a GWAS may reflect the ac-
tivity of one or more functional SNPs that have not
been investigated, e.g. because they are rare or not
genotyped.
Conclusions
We propose that the AS-SNP rs4846913 and rs2144300
drive the association to HDL-C plasma levels through an
inhibitory regulation of GALNT2 rather than the re-
ported GWAS SNP rs4846914. The luciferase assays
data show a decrease in the functional activity of the
construct harboring the C allele of the AS-SNP
rs4846913, activity that was further lowered by the pres-
ence of the C allele of rs2144300 suggesting a synergistic
inhibitory role and leading to the hypothesis that the
low activity alleles rs4846913-C and rs2144300-C are
preferentially bound by transcriptional repressors result-
ing in lower GALNT2 levels and higher HDL-C.
Fig. 1 Functional effect of rs4846913 and rs2144300 at GALNT2 in HepG2 cells. a UCSC Genome browser view of rs4846913 (orange) and
associated GWAS-SNPs (cyan). The transcription factor ChIP-seq track from ENCODE shows the TF binding sites overlapping the different SNPs.
The embedded regional LD plot (SNAP tool [11]) represents the genetic region around rs4849613 with SNPs in high LD (r2 > 0.8). The GWAS-SNPs
associated are indicated in cyan. b EMSA for the C- and A-alleles of rs4846913. Lanes 3 and 4 represent a competition assay where a 100-fold
molar excess of unlabeled probes was added to biotinylated probes and HepG2 nuclear protein extract. c Dual luciferase assay testing the enhancer
activity of two constructs with the C- and A-alleles of rs4846913 and the C- and T alleles of rs2144300. * P < 0,001
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